SI2547205T1 - Novi postopki za ciljanje rakastih matičnih celic - Google Patents

Novi postopki za ciljanje rakastih matičnih celic

Info

Publication number
SI2547205T1
SI2547205T1 SI201132110T SI201132110T SI2547205T1 SI 2547205 T1 SI2547205 T1 SI 2547205T1 SI 201132110 T SI201132110 T SI 201132110T SI 201132110 T SI201132110 T SI 201132110T SI 2547205 T1 SI2547205 T1 SI 2547205T1
Authority
SI
Slovenia
Prior art keywords
stem cells
cancer stem
novel methods
targeting cancer
targeting
Prior art date
Application number
SI201132110T
Other languages
English (en)
Slovenian (sl)
Inventor
Chiang Jia Li
David Leggett
Youzhi Li
Wei Li
Original Assignee
1Globe Biomedical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1Globe Biomedical Co., Ltd. filed Critical 1Globe Biomedical Co., Ltd.
Publication of SI2547205T1 publication Critical patent/SI2547205T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SI201132110T 2010-03-19 2011-03-21 Novi postopki za ciljanje rakastih matičnih celic SI2547205T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31589010P 2010-03-19 2010-03-19
US31588610P 2010-03-19 2010-03-19
US32581410P 2010-04-19 2010-04-19
PCT/US2011/029283 WO2011116399A1 (en) 2010-03-19 2011-03-21 Novel methods for targeting cancer stem cells
EP11757135.6A EP2547205B1 (en) 2010-03-19 2011-03-21 Novel methods for targeting cancer stem cells

Publications (1)

Publication Number Publication Date
SI2547205T1 true SI2547205T1 (sl) 2024-08-30

Family

ID=47678420

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201132110T SI2547205T1 (sl) 2010-03-19 2011-03-21 Novi postopki za ciljanje rakastih matičnih celic

Country Status (18)

Country Link
US (2) US9730909B2 (enExample)
EP (1) EP2547205B1 (enExample)
JP (1) JP2013522326A (enExample)
CN (1) CN103025159A (enExample)
AU (1) AU2011227023B2 (enExample)
BR (1) BR112012023660B8 (enExample)
CA (2) CA2793527A1 (enExample)
DK (1) DK2547205T3 (enExample)
ES (1) ES2987670T3 (enExample)
FI (1) FI2547205T3 (enExample)
HR (1) HRP20240658T1 (enExample)
LT (1) LT2547205T (enExample)
PL (1) PL2547205T3 (enExample)
RS (1) RS65536B1 (enExample)
RU (1) RU2591823C2 (enExample)
SI (1) SI2547205T1 (enExample)
SM (1) SMT202400193T1 (enExample)
WO (1) WO2011116399A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160430T1 (hr) 2007-09-10 2016-05-20 Boston Biomedical, Inc. Nova grupa inhibitora stat3 puta i inhibitora puta matičnih stanica karcinoma
CA2959951A1 (en) * 2010-03-19 2011-09-22 Boston Biomedical, Inc. Naphthofuran compounds and compositions for targeting cancer stem cells
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
EP3102036A4 (en) 2014-02-07 2017-09-20 Boston Biomedical, Inc. 3-substituted carbonyl-naphtho[2,3-b]furane derivative or pharmaceutically acceptable salt thereof
AU2015272560B2 (en) * 2014-06-09 2019-02-14 Kyoto Pharmaceutical Industries, Ltd. Novel anticancer agent
TW201713327A (zh) 2015-04-17 2017-04-16 波士頓生醫公司 治療癌症之方法
JP2018511645A (ja) 2015-04-17 2018-04-26 ボストン バイオメディカル， インコーポレイテッド 癌を治療するための方法
BR112017026025A2 (pt) 2015-06-03 2018-08-14 Boston Biomedical Inc composições que compreendem um inibidor de stemness de câncer e um agente imunoterápico para uso no tratamento de câncer
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
WO2017132049A1 (en) 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
CA3029596A1 (en) 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
US10926226B2 (en) * 2018-03-08 2021-02-23 ExxonMobil Research & Engineering Company Company Functionalized membranes and methods of production thereof
WO2020074010A1 (zh) 2018-10-12 2020-04-16 北京强新生物科技有限公司 治疗化疗难治性癌症的新联合用药方案
CN111825644B (zh) * 2019-04-18 2023-07-28 中国医学科学院药物研究所 2,3-二氢萘并[2,3-b]呋喃-4,9-二酮类化合物及其制备方法和用途
CN117350965A (zh) * 2023-10-07 2024-01-05 中国原子能科学研究院 对象内放射性微球的指标预估装置

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0402192A1 (fr) 1989-05-31 1990-12-12 BODET, Jean Augustin Article en carton ou matière analogue et procédé de fabrication
JPH04139177A (ja) 1989-12-28 1992-05-13 Dainippon Ink & Chem Inc フラルベンゾキノン誘導体及びその製造方法並びに制癌剤
JPH1121284A (ja) 1997-06-30 1999-01-26 Kotobuki:Kk フラノナフトキノン誘導体及びこれを含有する医薬
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
JP2003525862A (ja) 1999-01-27 2003-09-02 ザ ユニヴァーシティー オブ サウス フロリダ ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
MXPA02000828A (es) 1999-08-02 2002-07-30 Hoffmann La Roche Nuevos antagonistas retinoiides selectivos.
JP2001097860A (ja) 1999-09-29 2001-04-10 Japan Science & Technology Corp 抗薬剤耐性菌剤と抗クラミジア剤
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
US7998947B2 (en) 2001-03-28 2011-08-16 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
GB0117696D0 (en) * 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
WO2003045357A1 (en) 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
JP2005517637A (ja) 2001-11-29 2005-06-16 セラコス・インコーポレイテッド 体外フォトフォレーシスおよび／またはアポプトーシス細胞による一定の被験体を前処理するための方法
JP2005526084A (ja) 2002-03-15 2005-09-02 ナットイムネ・アクティーゼルスカブ マンノース結合レクチンを含む医薬組成物
AU2003275056A1 (en) * 2002-09-17 2004-04-08 Arqule, Inc. Novel lapacho compounds and methods of use thereof
AR042052A1 (es) * 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
IS6633A (is) 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
CA2528669A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20050049207A1 (en) 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
WO2005033048A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists
KR101218633B1 (ko) 2003-12-11 2013-01-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 세포 증식 질환 치료용 화합물
CA2563305A1 (en) 2004-04-09 2005-11-24 University Of South Florida Combination therapies for cancer and proliferative angiopathies
JP2004224802A (ja) 2004-04-21 2004-08-12 Japan Science & Technology Agency 抗菌剤
JP2008520612A (ja) 2004-11-24 2008-06-19 ノバルティス アクチエンゲゼルシャフト ＪＡＫ阻害剤およびＢｃｒ−Ａｂｌ、Ｆｌｔ−３、ＦＡＫまたはＲＡＦキナーゼ阻害剤のうち少なくとも１個の組合せ
JP2008535785A (ja) 2005-02-25 2008-09-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｓｔａｔ３の小分子阻害剤およびその使用
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP2006290871A (ja) 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
CN101142202A (zh) * 2005-03-16 2008-03-12 太日保日本株式会社 抗癌化合物及其中间体和生产方法
US20060252073A1 (en) 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
US20070243192A1 (en) 2006-02-21 2007-10-18 Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
JP5654233B2 (ja) 2006-03-31 2015-01-14 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 経口で生物学的に利用できるコーヒー酸関連抗癌剤
US20070238770A1 (en) 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
US8828451B2 (en) 2006-10-04 2014-09-09 University Of South Florida Akt sensitization of cancer cells
JP4077863B1 (ja) 2007-05-31 2008-04-23 タヒボジャパン株式会社 抗癌活性を有する光学活性２−（１−ヒドロキシエチル）−５−ヒドロキシナフト［２，３−ｂ］フラン−４，９−ジオンの製法
HRP20160430T1 (hr) * 2007-09-10 2016-05-20 Boston Biomedical, Inc. Nova grupa inhibitora stat3 puta i inhibitora puta matičnih stanica karcinoma
US20100298402A1 (en) 2007-11-06 2010-11-25 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors
CA2959951A1 (en) * 2010-03-19 2011-09-22 Boston Biomedical, Inc. Naphthofuran compounds and compositions for targeting cancer stem cells

Also Published As

Publication number Publication date
PL2547205T3 (pl) 2024-07-08
EP2547205B1 (en) 2024-03-20
AU2011227023A1 (en) 2012-09-27
HRP20240658T1 (hr) 2024-08-16
US20130028944A1 (en) 2013-01-31
BR112012023660B8 (pt) 2021-05-25
CN103025159A (zh) 2013-04-03
BR112012023660A2 (pt) 2015-09-15
AU2011227023B2 (en) 2015-05-28
SMT202400193T1 (it) 2024-07-09
US9730909B2 (en) 2017-08-15
RU2591823C2 (ru) 2016-07-20
CA2946890A1 (en) 2011-09-22
DK2547205T3 (da) 2024-05-27
JP2013522326A (ja) 2013-06-13
LT2547205T (lt) 2024-06-10
CA2793527A1 (en) 2011-09-22
BR112012023660B1 (pt) 2021-05-18
EP2547205A4 (en) 2013-08-14
EP2547205A1 (en) 2013-01-23
US20170319537A1 (en) 2017-11-09
FI2547205T3 (fi) 2024-05-27
RU2012144420A (ru) 2014-04-27
RS65536B1 (sr) 2024-06-28
ES2987670T3 (es) 2024-11-15
WO2011116399A1 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
LT2547205T (lt) Nauji tikslinio poveikio vėžio kamieninėms ląstelėms būdai
IL220756A0 (en) Herbicide-tolerant plants
IL225635A (en) Device for cell culture with internal tools
PT2785834T (pt) Composição de células estaminais melhorada
PT2547205T (pt) Novos métodos para atingir células estaminais cancerígenas
EP2601290A4 (en) SOMATIC STEM CELLS
EP2772268B8 (en) Cancer stem cell-specific molecule
GB201016139D0 (en) Cancer phosholipidome
PL2547766T3 (pl) Rośliny tolerancyjne względem herbicydów
EP2760996A4 (en) SOMATIC STEM CELLS
IL255309B (en) Reprogramming of cancer cells
GB201012590D0 (en) Methods for diagnosing cancer
WO2011116344A9 (en) Targeting cancer stem cells
EP2533789A4 (en) METHOD FOR IMPROVING THE FUNCTIONALITY OF SPERM
PL2831110T3 (pl) Terapia anty-EMP2 zmniejsza ilość rakowych komórek macierzystych
PL3536334T3 (pl) Szczepionki przeciw rakowi ukierunkowane na komórki macierzyste raka
PL2568796T3 (pl) Półzawieszany pług obracalny
WO2012106368A9 (en) Methods for inhibiting prostate cancer
SG196714A1 (en) Cancer stem cell inhibition
GB201021372D0 (en) CD24 cancer stem cell
ZA201205860B (en) Herbicide-tolerant plants
AU2011900981A0 (en) Inhibition of cancer stem cells
GB201012495D0 (en) Targeted differntiation of stem cells
EP2593113A4 (en) CELL THERAPY
GB201020580D0 (en) Cells